Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 7:12:593572.
doi: 10.3389/fnagi.2020.593572. eCollection 2020.

The Future of GDNF in Parkinson's Disease

Fredric P Manfredsson  1 , Nicole K Polinski  2 , Thyagarajan Subramanian  3 , Nicholas Boulis  4 , Dustin R Wakeman  5   6 , Ronald J Mandel  7
Affiliations

The Future of GDNF in Parkinson's Disease

Fredric P Manfredsson et al. Front Aging Neurosci. .
No abstract available

Keywords: GDNF (glial cell line-derived neurotrophic factor); Parkinson's disease; clinical trial (2.172); gene therapy (GT); neurotrophic factor; neurturin.

PubMed Disclaimer

Conflict of interest statement

DW was employed by Virscio, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Airavaara M., Harvey B. K., Voutilainen M. H., Shen H., Chou J., Lindholm P., et al. . (2012). CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice. Cell Transpl. 21, 1213–1223. 10.3727/096368911X600948 - DOI - PMC - PubMed
    1. Baek J. Y., Jeong J. Y., Kim K. I., Won S. Y., Chung Y. C., Nam J. H., et al. . (2018). Inhibition of microglia-derived oxidative stress by ciliary neurotrophic factor protects dopamine neurons in vivo from MPP(+) neurotoxicity. Int. J. Mol. Sci. 19:3543. 10.3390/ijms19113543 - DOI - PMC - PubMed
    1. Bartus R. T., Herzog C. D., Chu Y., Wilson A., Brown L., Siffert J., et al. . (2011). Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov. Disord. 26, 27–36. 10.1002/mds.23442 - DOI - PMC - PubMed
    1. Berg D., Adler C. H., Bloem B. R., Chan P., Gasser T., Goetz C. G., et al. . (2018). Movement disorder society criteria for clinically established early Parkinson's disease. Mov. Disord. 33, 1643–1646. 10.1002/mds.27431 - DOI - PubMed
    1. Budman E., Deeb W., Martinez-Ramirez D., Pilitsis J. G., Peng-Chen Z., Okun M. S., et al. . (2018). Potential indications for deep brain stimulation in neurological disorders: an evolving field. Eur. J. Neurol. 25, 434–e30. 10.1111/ene.13548 - DOI - PubMed